Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance

Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance

Resistance of acute myeloid leukemia to current therapies leads to frequent relapses. Identification of molecular mechanisms involved in chemoresistance constitutes a key challenge to define new therapeutic concepts. Here, we show that the ATR/CHK1 pathway, essential in maintaining genomic stability...

Full description

Bibliographic Details
Main Authors:	Laure David, Stéphane Manenti, Christian Récher, Jean-Sébastien Hoffmann, Christine Didier
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-09-01
Series:	Molecular & Cellular Oncology
Subjects:	acute myeloid leukemia atr and chk1 kinases chemoresistance dna replicative stress
Online Access:	http://dx.doi.org/10.1080/23723556.2017.1289293

Similar Items

Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy
by: Salman Ahmed, et al.
Published: (2022-11-01)

Prospects for the Use of ATR Inhibitors to Treat Cancer
by: Scott H. Kaufmann, et al.
Published: (2010-04-01)

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
by: Patrycja Gralewska, et al.
Published: (2020-04-01)

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer
by: Yuchen Guo, et al.
Published: (2021-10-01)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous <i>BRCA<sup>MUT</sup></i> and <i>BRCA<sup>WT</sup></i> Ovarian Cancer Cells
by: Patrycja Gralewska, et al.
Published: (2022-06-01)

Duox-generated reactive oxygen species activate ATR/Chk1 to induce G2 arrest in Drosophila tracheoblasts
by: Amrutha Kizhedathu, et al.
Published: (2021-10-01)

Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia
by: Lili Feng, et al.
Published: (2023-09-01)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched <i>BRCA2</i> Mutant and Corrected Cells
by: Hannah L Smith, et al.
Published: (2020-04-01)

Targeting the ATR-CHK1 Axis in Cancer Therapy
by: Stuart Rundle, et al.
Published: (2017-04-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
by: Lukas Gorecki, et al.
Published: (2021-02-01)

β3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic Cells Survival and Chemoresistance
by: Maura Calvani, et al.
Published: (2020-06-01)

Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation
by: Jun Luo, et al.
Published: (2020-02-01)

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
by: Patrycja Gralewska, et al.
Published: (2020-12-01)

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets
by: Amalia Sofianidi, et al.
Published: (2024-03-01)

Negative regulation of G2-M by ATR (mei-41)/Chk1(Grapes) facilitates tracheoblast growth and tracheal hypertrophy in Drosophila
by: Amrutha Kizhedathu, et al.
Published: (2018-04-01)

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling
by: Styliani Karanika, et al.
Published: (2017-02-01)

MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
by: Emeline Bollaert, et al.
Published: (2021-05-01)

Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs
by: Beatriz Hernández-Suárez, et al.
Published: (2023-08-01)

The Role of Forkhead Box Proteins in Acute Myeloid Leukemia
by: Carmelo Gurnari, et al.
Published: (2019-06-01)

Olaparib-Resistant <i>BRCA2</i><sup>MUT</sup> Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
by: Łukasz Biegała, et al.
Published: (2023-03-01)

A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
by: Yunxin Zeng, et al.
Published: (2021-11-01)

Harnessing DNA Replication Stress for Novel Cancer Therapy
by: Huanbo Zhu, et al.
Published: (2020-08-01)

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
by: Angélique Bruyer, et al.
Published: (2023-12-01)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
by: Andrea Ghelli Luserna Di Rorà, et al.
Published: (2019-10-01)

Sorafenib regulates c-CBL gene-mediated chemoresistance in acute myeloid leukemia cells
by: Qixin Sun, et al.
Published: (2023-12-01)

The kinase domain residue serine 173 of Schizosaccharomyces pombe Chk1 kinase is critical for the response to DNA replication stress
by: Naomi Coulton, et al.
Published: (2017-12-01)

The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?
by: Atousa Haghi, et al.
Published: (2022-10-01)

Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
by: Jan Stetka, et al.
Published: (2020-04-01)

APE2 Is a General Regulator of the ATR-Chk1 DNA Damage Response Pathway to Maintain Genome Integrity in Pancreatic Cancer Cells
by: Md Akram Hossain, et al.
Published: (2021-11-01)

Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
by: Alvina I. Khamidullina, et al.
Published: (2024-01-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

Periodontal Pathogens Promote Oral Squamous Cell Carcinoma by Regulating ATR and NLRP3 Inflammasome
by: Yufei Yao, et al.
Published: (2021-09-01)

Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine
by: Zay Yar Oo, et al.
Published: (2019-07-01)

When heat casts a spell on the DNA damage checkpoints
by: Thomas Turner, et al.
Published: (2014-01-01)

Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer
by: Kalil Batnini, et al.
Published: (2022-08-01)

The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin
by: Haochen Su, et al.
Published: (2023-10-01)

Distinct cellular responses to replication stress leading to apoptosis or senescence
by: Emilie Lukášová, et al.
Published: (2019-05-01)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
by: Øystein Bruserud, et al.
Published: (2023-07-01)

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells
by: David King, et al.
Published: (2021-12-01)